Vertex Pharmaceuticals
W19.1- Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study
Friday, October 24, 202510:15 AM - 12:15 PM PDT